Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rajarethinam, Rajaprabhakaran
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder	Recruiting	3	700	US	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	12/24	12/24
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder	Recruiting	3	150	Europe, Canada, US	Ecopipam, Ecopipam Hydrochloride	Emalex Biosciences Inc.	Tourette Syndrome	11/24	03/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults	Recruiting	3	196	Europe, Canada, US, RoW	Ecopipam Hydrochloride	Emalex Biosciences Inc.	Tourette Disorder	12/24	12/24
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD	Recruiting	3	568	Europe, Canada, US	Psilocybin, COMP360	COMPASS Pathways	Treatment Resistant Depression	03/25	05/25
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes	Active, not recruiting	N/A	300	US		LivaNova	Treatment Resistant Depression	10/24	10/24